Archive for June 25, 2017

Risk Factors for 30-Day Mortality in Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

International Journal of Infectious Diseases August 2017 V.61 P.3-6

Pedro Ayau, Ana C. Bardossy, Guillermo Sanchez, Ricardo Ortiz, Daniela Moreno, Pamela Hartman, Khulood Rizvi, Tyler C. Prentiss, Mary B. Perri, Meredith Mahan, Vanthida Huang, Katherine Reyes, Marcus J. Zervos

Highlights

  • The aim of this study was to identify risk factors associated with 30-day mortality in patients with MRSA BSI.
  • 1,168 patients with confirmed MRSA BSI were identified over a 9-year period in which 30-day all-cause mortality was 16%.
  • There was no significant variability in 30-day mortality over our 9-year study period.
  • Our study showed that age, cancer, heart disease, neurologic disease, nursing home residence and Charlson score >3 are risk factors for 30-day mortality in patients with MRSA BSI.
  • Diabetes, PVD and readmission because of infection have statistically significant protective effects on 30-day mortality

Objectives

Methicillin-resistant Staphylococcus aureus (MRSA) blood stream infections (BSI) are a major health care problem accounting for a large percentage of nosocomial infections. The aim of this study was to identify risk factors associated with 30-day mortality in patients with MRSA BSI.

Methods

This was a retrospective study performed in Southeast Michigan. Over a 9- year period, a total of 1,168 patients were identified with MRSA BSI. Patient demographics and clinical data were retrieved and evaluated using electronic medical health records.

Results

30-day mortality during the 9-year study period was 16%. Significant risk factors for 30-day mortality were age, cancer, heart disease, neurologic disease, nursing home residence and Charlson score >3 with Odds Ratio (OR) of 1.03 (CI 1.02–1.04), 2.29 (CI 1.40–3.75), 1.78 (CI 1.20–2.63), 1.65 (CI 1.08–2.25), 1.66 (CI 1.02 − 2.70) and 1.86 (CI 1.18 − 2.95) correspondingly. Diabetes mellitus, peripheral vascular disease (PVD), and readmission were protective factors for 30-day mortality with OR of 0.53 (CI 0.36–0.78), 0.46 (CI 0.26–0.84) and 0.13 (CI0.05 − 0.32) respectively.

Conclusions

Our study identified significant risk factors for 30-day mortality in patients with MRSA BSI. Interestingly, diabetes mellitus, PVD and readmission were protective effects on 30-day mortality. There was no statistically significant variability in 30-day mortality over the 9-year study period.

PDF

http://www.ijidonline.com/article/S1201-9712(17)30146-7/pdf

 

Advertisements

June 25, 2017 at 1:43 pm

Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia

International Journal of Infectious Diseases August 2017 V.61 P.23–26

Jiawei Zeng, Lidan Zhang, Min Gao, Jingjing Wu, Haiyan Wu, Jie Chen, Xiao Chen, Wen Tang

Highlights

  • A case of extensively drug-resistant Acinetobacter baumannii bacteremia in an immunocompetent infant is reported.
  • Tigecycline was used successfully with monitoring of trough serum concentrations to address its safety, efficacy, and pharmacokinetics.
  • This is the first report of tigecycline monitoring in a pediatric patient with bloodstream infection​, and it is worth monitoring drug concentrations.
  • This is the youngest case treated with tigecycline for A. baumannii bacteremia according to the published literature.
  • Tigecycline can be given for life-threatening infections in children for whom no better alternative antimicrobial options are available.

The successful use of tigecycline in a 12-month old liver transplant recipient with extensively drug-resistant Acinetobacter baumannii bacteremia is presented.

Tigecycline serum concentrations were monitored to help improve antibiotic efficacy and minimize side effects.

A literature review identified 11 additional pediatric cases of A. baumannii infection treated with tigecycline since 2011.

Tigecycline treatment should be considered in children with extensively drug-resistant bacterial infections.

PDF

http://www.ijidonline.com/article/S1201-9712(17)30149-2/pdf

June 25, 2017 at 1:39 pm

Actividad comparativa in vitro entre linezolid y tedizolid frente a aislados clínicos de Staphylococcus aureus resistentes a meticilina y aislados resistentes también a linezolid

Revista Española de Quimioterapia Octubre 2016 V.29 N.5

MARINA PEÑUELAS, FRANCISCO JAVIER CANDEL, CLARA LEJARRAGA,  LAURA LÓPEZ-GONZÁLEZ, JOSE MANUEL VIÑUELA-PRIETO, DIEGO LÓPEZ DE MENDOZA

PDF

http://www.seq.es/seq/0214-3429/29/5/penuelas30jun2016.pdf

June 25, 2017 at 12:07 pm


Calendar

June 2017
M T W T F S S
« May   Jul »
 1234
567891011
12131415161718
19202122232425
2627282930  

Posts by Month

Posts by Category